In a nutshell This study aimed to investigate the long-term treatment outcomes and prognostic factors of acute lymphoblastic leukemia (ALL) in pediatric patients who took part in the SCMC-ALL-2009 trials. This study concluded that the long-term outcomes were favorable for these patients and better for low-risk patients...
Read More
In a nutshell This study aimed to investigate the relationship between time from diagnosis to treatment start and outcomes for patients with acute myeloid leukemia. This study concluded that time from diagnosis to treatment is not related to survival in these patients. Some background Untreated acute myeloid leukemia...
Read More
In a nutshell This study aimed to investigate fatigue (tiredness) as a side effect of tyrosine kinase treatment in patients with chronic myeloid leukemia and its relationship to physical activity. This study concluded that identifying patients at risk of severe fatigue and working to reduce fatigue during treatment of...
Read More
In a nutshell This study aimed to investigate if blinatumomab was an effective treatment in patients with minimal residual disease B-cell precursor acute lymphoblastic leukemia. This study concluded that complete minimal residual response during blinatumomab treatment can be a potentially...
Read More
In a nutshell This study aimed to investigate the safety and effectiveness of the combination of all-trans-retinoic acid (Vesanoid), arsenic trioxide (Trisenox), and idarubicin (Idamycin) as front-line treatment for acute promyelocytic leukemia. This study concluded that this combination is safe and effective for these...
Read More
In a nutshell This study aimed to compare the safety and effectiveness of bendamustine–rituximab (BR) and chlorambucil–rituximab (Chl-R) as a front-line treatment in older patients with chronic lymphocytic leukemia (CLL). This study concluded that both treatments are good options for these...
Read More
In a nutshell This study aimed to investigate the impact of time to response to treatment on the outcomes of patients with accelerated-phase chronic myeloid leukemia. This study concluded that an early response to treatment is strongly associated with long-term survival in these patients. Some background Tyrosine...
Read More
In a nutshell This study aimed to investigate the safety and effectiveness of combining daunorubicin (Cerubidine) and cytarabine (Cytosar-U) compared to idarubicin (Idamycin) and cytarabine as induction treatment for patients with acute myeloid leukemia. This study concluded that the idarubicin and cytarabine combination...
Read More
In a nutshell This study aimed to investigate the impact of a pharmaceutical care program on the safety and effectiveness of ibrutinib in patients with chronic lymphocytic leukemia. This study concluded that management of ibrutinib treatment by using a pharmaceutical care program results in improved survival and better...
Read More
In a nutshell This study aimed to compare two salvage regimes for patients with relapsed/refractory acute myeloid leukemia. This study concluded that both regimens have similar effectiveness in terms of overall response but one shows a significant reduction in side effects in these patients. Some background...
Read More
In a nutshell This study aimed to investigate the occurrence of atrial fibrillation (abnormal heart rhythm) in patients with chronic lymphocytic leukemia who are treated with ibrutinib. This study concluded that atrial fibrillation does not require ibrutinib treatment to be stopped but is associated with worse outcomes for...
Read More
In a nutshell This study aimed to investigate cytarabine (Cytosar-U), aclarubicin (Aclacin) and G-CSF (Neupogen) as a salvage treatment for adult patients with relapsed or refractory T cell acute lymphoblastic leukemia. This study concluded that this treatment combination is safe and effective as a salvage treatment...
Read More
